United Kingdom Advanced Therapy Medicinal Products CDMO Market Insight
The United Kingdom Advanced Therapy Medicinal Products CDMO Market is growing at an 19.01% CAGR, driven by rising demand for cell and gene therapies, expanding clinical pipelines, regulatory support from MHRA, and investments in biomanufacturing, partnerships, and viral vector technologies, enhancing scalability and commercialization.
United Kingdom Advanced Therapy Medicinal Products CDMO Market Insights Forecasts to 2035
- The United Kingdom Advanced Therapy Medicinal Products CDMO Market Size Was Estimated at USD 443.3 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 19.01% from 2025 to 2035
- The United Kingdom Advanced Therapy Medicinal Products CDMO Market Size is Expected to Reach USD 2526.2 Million by 2035
Notable Insights for United Kingdom Advanced Therapy Medicinal Products CDMO Market
- By service type, viral vector manufacturing dominated, accounting for approximately 40–45% share in 2024, driven by gene therapy demand.
- By therapy type, gene therapies and cell therapies together held approximately 65–70% share, due to increasing approvals and late-stage clinical trials.
- Approximately 30–35% of ATMP developers in the UK rely on CDMOs for manufacturing, reflecting the complexity and capital-intensive nature of production.
- Around 60–70% of biotech firms prefer outsourcing to CDMOs to accelerate time-to-market and ensure regulatory compliance.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Advanced Therapy Medicinal Products CDMO Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Advanced Therapy Medicinal Products CDMO Market
- Lonza Group
- Oxford Biomedica
- Catalent
- WuXi Advanced Therapies
- Thermo Fisher Scientific
- Charles River Laboratories
- Samsung Biologics
- Recipharm
- Others
Recent Developments:
- In June 2024: NIHR Innovation Observatory reported over 540 ATMPs in development, with gene therapies comprising around 57% of the pipeline, highlighting strong demand for UK CDMO manufacturing services.
- In June 2023: Cell and Gene Therapy Catapult joined the SMARTER consortium with Achilles Therapeutics to develop smart, scalable cell therapy manufacturing using advanced analytics and Process Analytical Technologies.
Market Segmentation:
United Kingdom Advanced Therapy Medicinal Products CDMO Market, By Service Type
- Cell Therapy Manufacturing
- Gene Therapy Manufacturing
- Viral Vector Production
- Process Development
- Analytical & Quality Testing
United Kingdom Advanced Therapy Medicinal Products CDMO Market, By Therapy Type
- Gene Therapy
- Cell Therapy
- Tissue-Engineered Products
United Kingdom Advanced Therapy Medicinal Products CDMO Market, By End User
- Biopharmaceutical Companies
- Biotechnology Companies
- Academic & Research Institutes
United Kingdom Advanced Therapy Medicinal Products CDMO Market, By Phase
- Preclinical
- Clinical
- Commercial
Expert Views:
The UK ATMP CDMO Market is expected to witness robust growth due to the expanding pipeline of advanced therapies and increasing outsourcing trends among biotech firms. Experts highlight that viral vector manufacturing will remain a critical bottleneck and opportunity area. Support from institutions like the National Health Service and regulatory facilitation is accelerating clinical adoption. Additionally, advancements in automation, closed-system manufacturing, and AI-driven process optimization are expected to enhance efficiency, reduce costs, and drive long-term market expansion through 2035.